Dossier assessment
Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) – Benefit assessment according to § 35a SGB V
Report documents
-
Extract of dossier assessment
Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) – Benefit assessment according to § 35a SGB V
-
Dossier assessment
Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) – Benefit assessment according to § 35a SGB V
Dossier assessment
Adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive
Added benefit not proven
Project details
- Project no.
- A22-74
- Commission
- Commission awarded on 19.07.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Inebilizumab (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Inebilizumab (immunoglobulin G4-related disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed